Trial
NCT01093846
38 Week Extension Study to CAIN457C2303
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Uveitis
Intervention
AIN457
Why stopped
Core Study in Behcet's disease with mostly active uveitis did not meet its primary endpoint
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-02-22